180 Life Sciences Corp. Files 8-K on Director/Officer Changes
Ticker: FRMM · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1690080
Sentiment: neutral
Topics: corporate-governance, management-change
TL;DR
180 Life Sciences filed an 8-K detailing director/officer changes and compensation.
AI Summary
180 Life Sciences Corp. filed an 8-K on December 4, 2024, reporting on events as of December 2, 2024. The filing covers the departure of directors, election of directors, appointment of officers, and compensatory arrangements. It also includes Regulation FD disclosures, other events, and financial statements/exhibits.
Why It Matters
This 8-K filing indicates significant changes in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors and officers can signal shifts in company strategy or internal dynamics, requiring closer monitoring.
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- KBL Merger Corp. IV (company) — Former Company Name
FAQ
What specific events are detailed in the 8-K filing dated December 4, 2024?
The filing details the departure of directors, election of directors, appointment of certain officers, and compensatory arrangements for certain officers, along with Regulation FD disclosures and other events.
What is the exact name of the registrant?
The exact name of the registrant is 180 Life Sciences Corp.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 2, 2024.
What was the former name of 180 Life Sciences Corp.?
The former name of 180 Life Sciences Corp. was KBL Merger Corp. IV.
What is the Standard Industrial Classification code for 180 Life Sciences Corp.?
The Standard Industrial Classification code for 180 Life Sciences Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,784 words · 7 min read · ~6 pages · Grade level 10.7 · Accepted 2024-12-04 08:00:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
- $50,000 — r provides for Mr. Shoemaker to be paid $50,000 per year as an annual retainer fee for
- $2 billion — ver his career, he has raised more than $2 billion across multiple Chief Executive Officer
Filing Documents
- ea0223540-8k_180life.htm (8-K) — 74KB
- ea022354001ex10-1_180life.htm (EX-10.1) — 15KB
- ea022354001ex99-1_180life.htm (EX-99.1) — 15KB
- ex10-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-105251.txt ( ) — 340KB
- atnf-20241202.xsd (EX-101.SCH) — 4KB
- atnf-20241202_def.xml (EX-101.DEF) — 26KB
- atnf-20241202_lab.xml (EX-101.LAB) — 36KB
- atnf-20241202_pre.xml (EX-101.PRE) — 25KB
- ea0223540-8k_180life_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 180 LIFE SCIENCES CORP. Date: December 4, 2024 By: /s/ Blair Jordan Blair Jordan Interim Chief Executive Officer 4